Moreover, SIRT6 expression is associated with poor prognosis of breast, gastric, colorectal, and lung cancer patients (19, 22–24), and higher SIRT6 expression is associated with chemoresistance (25, 26). Here, SIRT6 is linked to lung carcinoma.